1. Unilateral and bilateral injections of 1 0 1l. solutions of angiotensin II into specific brain sites produced copious drinking of water in the waterreplete rhesus monkey (Macaca mulatta).
L. G. SHARPE AND L. W. SWANSON most potent dipsogen, followed by Ile8-angiotensin II. The 1-7 heptapeptide, des-Phe8-angiotensin II was an ineffective dipsogen. Carbachol microinjected into the most sensitive angiotensin drinking sites had no dipsogenic action in the water-replete monkey.
6. Tachyphylaxis to angiotensin II was demonstrated as a reduction in mean water intake of 55 and 74 per cent on the second and third microinjections, respectively. This reduction appeared to be due to dilutional inhibition or signals from the amount of water ingested on the first microinjection of angiotensin II. 7. Monkeys drank an amount equal to a normal daily intake following two to three microinjections of angiotensin II in doses of 100-250 ng into sensitive regions. This extra water load caused no reductions in normal daily water intake either for the remainder of the experimental day or 24 hr later.
8. Pre-treatments with microinjections of an angiotensin-converting enzyme inhibitor, SQ 20,881, did not reduce the dipsogenic action of angiotensin I, suggesting that this and perhaps other peptide precursors act directly on receptor mechanisms to produce drinking. Attempts to change the polydipsic effects of angiotensin II were unsuccessful with pre-treatments of intracranial microinjections of either haloperidol, Ile8-angiotensin II or carbachol. 9. Microinjections of angiotensin II dissolved in hypertonic saline solutions had no influence on water intake when compared with the same dose dissolved in distilled water or isotonic saline.
10. Yawning was the only other response that appeared to be related directly to intracranial injections of angiotensin II. In some instances, a hyperactive state of the animal followed intraventricular injections of angiotensin II. In other instances, intracranial microinjections of angiotensin II were followed by quietude or e.e.g. and behavioural signs of light sleep.
11. This work further confirms the findings of previous research which showed that angiotensin II is the most potent dipsogen in all species tested to date. This endogenous peptide appears to participate in natural thirst by acting on central mechanisms of extracellular thirst. INTRODUCTION Angiotensin II has been shown to evoke copious drinking when injected into the diencephalon and cerebral ventricles of the rat (Booth, 1968; Epstein, Fitzsimons & Rolls, 1970; Severs, Summy-Long, Taylor & Connor, 1970; , cat (Sturgeon, Brophy & Levitt, 1973) , goat (Andersson & Eriksson, 1971) , and monkey (Setler, 1971; Myers, Hall 596 INTRACRANIAL ANGIOTENSIN AND THIRST & Rudy, 1973) . Drinking in response to intracranial angiotensin II has also been observed in the rabbit (see Fitzsimons, 1972; L. G. Sharpe, N. Olsen & E. Bischoff, unpublished observations) and the Barbary dove (see Fitzsimons, 1972) . Angiotensin II has been shown to be a more potent dipsogen than the cholinomimetic carbachol when injected by the intracranial route (Epstein et al. 1970; Swanson, Sharpe & Griffin, 1973) . In addition, its dipsogenic action is not restricted to the rat, as is the case with carbachol (Myers & Sharpe, 1968; Fitzsimons, 1972) .
Angiotensin II-induced drinking is similar to normal thirst since the response is specific and strongly motivational and other responses such as hyperactivity and feeding are either absent or inhibited (Epstein et al. 1970; McFarland & Rolls, 1972; Rolls, Jones & Fallows, 1972) . When intracranial microinjections of angiotensin II are made in conjunction with cellular and extracellular stimuli to thirst, the amount of drinking is potentiated when compared to these stimuli given alone (Fitzsimons, 1970) . Because of the above evidence, combined with the fact that angiotensin II is a polypeptide endogenously released by renin, it has been postulated that the renin-angiotensin system participates in normal thirst by sensitizing specific neural circuits in the brain that mediate drinking behaviour (Fitzsimons, 1970 (Fitzsimons, , 1972 . However, the central pharmacological mechanism of the angiotensin II drinking response is far from clear. In the present study we have examined in detail some of the characteristics of angiotensin II-induced drinking, as well as the distribution of angiotensin II-sensitive sites in the brain of rhesus monkeys. METHODS Animals. Seven adult rhesus monkeys, three females, and four males, weighing between 4-25 and 8 kg were adapted to primate restraining chairs throughout experimentation. All animals had free access to food and water at all times and were maintained on a 12-hr lights on 12-hr lights off schedule. Surgical procedure. A previously described cannula array system was implanted under aseptic conditions (Sharpe & Myers, 1969; ). The cannulae consisted of 23 gauge (0-64 mm o.d.) stainless-steel tubing with 30 gauge (0.30 mm o.d.) stainless-steel inner stilettes inserted to prevent blockage. All monkeys had a fourcannula system with the tips stereotaxically implanted above target sites in the diencephalon and the mid-brain-pons using the coordinates of Russell (1961) or Snider & Lee (1961) . Bilateral placements were made in the septum, anterior hypothalamic-medial preoptic region, lateral ventricles and the metencephalon. Unilateral placements were made at mid line locations in the third ventricle, thalamus and mid-brain. The number of animals receiving microinjections at various loci is presented in Table 1 .
In four animals, a small thermistor was implanted between the cerebral hemispheres next to the falx cerebri 5-7 mm below dura. Leads from the thermistor were attached to a receptacle which was permanently fixed to the skull so that brain temperature could be recorded by inserting into the receptacle a plug with wires 597 598 L. G. SHARPE AND L. W. SWANSON leading to a telethermometer. We have found that recording brain temperature is convenient and is a good index of body temperature since it parallels closely colonic temperature.
Recordings of e.e.g. were made from small stainless-steel screws placed bilaterally on the surface of the dura mater in the parietal and occipital regions of the cortex. Eye movements were recorded from stainless-steel screws placed lateral to the orbital crest. An electromyogram was recorded from stainless-steel wire loops placed in the temporal musculature. All wires from the recording electrodes were fixed to a common connector receptacle attached to the skull. All cannulae, electrodes and connectors were permanently fixed to the skull with stainless-steel 'anchor' screws and cranioplastic cement (methyl methacrylate co-polymer).
Microinjection procedure. At least 1 week of post-operative recovery was allowed before beginning microinjections, at which time eating and drinking were back to pre-operative intake levels. The stilette was removed and a 30 gauge stainless-steel inner injection cannula was inserted into the 23 gauge outer guide cannula to the desired depth in the brain. Drug solutions were injected in volumes of 1-0 /Zl. via a 1-0 m length of PE 10 tubing connected to the inner injection cannula with a 50 #1.
syringe. The accuracy of this volume was determined by the movement of a short air space in a calibrated segment of the PE 10 tubing using a micrometer drive system (Swanson, Perez & Sharpe, 1972) . The rate of injection was 1-0 ,ul. in 30 sec.
Depending on the length of the inner injection cannula, microinjections were made from 1 to 7 mm below the tips of the implanted guide cannulae. The injection system remained attached to the restrained monkey so that unilateral or bilateral microinjections could be made at any time with minimum procedural disturbance to the animal. The experimental arrangement is pictured in PI. 1.
Unless stated otherwise, microinjections were given only after a 30 min base line of no ingestive behaviour. When feasible, three microinjections were given during an experimental day with at least 1 hr between microinjections. Experimental days were separated by one or more non-experimental days.
Animals obtained food by self-feeding with a continuous supply of commercially provided monkey chow. Water was obtained from an inverted 500 ml. graduated cylinder (see PI. 1). Food consumption was measured to the nearest gram and water consumption to the nearest 5 ml. During an experimental day, records of food and water intake, respiratory rates and temperature were taken every 15 min.
Intake latencies for food and water were recorded to the nearest 0-5 min and were defined as the time interval between the end of a microinjection and the start of drinking or eating. Other activities such as yawning, drowsiness, sleeping, shivering, vocalizing, hyperactivity and sexual behaviour were also recorded. Water intake for all monkeys was also recorded every 24 hr, at 0900 hr, for the entire duration of restraint.
A total of forty e.e.g. records, each from 1 to 2 hr long, were monitored during microinjection experiments with angiotensin II. All surface e.e.g. recordings were made on a six-channel Grass polygraph unit operated at paper speeds of 15 mm per second. Chemical materials. Unless stated otherwise, synthetic valine5-angiotensin II amide (Hypertensin CIBA) was dissoved in sterile 0-9 % (w/v) NaCl, as were other substances. The angiotensin II analogues Ile8-angiotensin II; Phe4, Tyr8-angiotensin II (P4T8); des-Phe8-angiotensin II (a 1-7 heptapeptide), and angiotensin I were generously supplied by Drs G. R. Marshall and P. Needleman (Marshall & Merrifield, 1965; Marshall, Vine & Needleman, 1970) . Angiotensin I (Ile5-angiotensin I) was also generously supplied by Schwarz/Mann. Haloperidol (Haldol, 1 ml. ampoules, 5 mg/ ml., McNeil Laboratories) was administered undiluted in 1 0 and 2-0 j/l. volumes.
Other drugs were carbamylcholine chloride (carbachol, Sigma Chemical Co.) and an inhibitor of the enzyme which converts angiotensin I to angiotensin II, SQ 20,881 (generously supplied by the Squibb Institute).
Hi8tology. At the conclusion of the experiments, the brains were perfused in ittU with 10 1. of a fixative solution (1.5 % glutaraldehyde plus 2 0 % paraformaldehyde in phosphate buffer). The brains were fixed with the inner injection cannula intact.
For determining the precise localization of each cannula, frontal serial sections were cut at 24 pu and stained for cells and fibres following a modified Kluver-Barrera method (Wolf, 1971) .
RE3SULTS
Drinking in response to intracranial angiotensin II and anatomical mapping A total of 368 microinjections of angiotensin II at various doses were made into six general regions of the brain of water-satiated monkeys ( Table 1 ). In three of these regions, drinking without eating was produced following bilateral and unilateral injections of angiotensin II in doses ranging from 0.5 to 1000 ng. In all references to bilateral microinjections, the stated dose is given in the right as well as the left hemisphere. For example, in a 50 ng bilateral injection, 50 ng is administered in both the right cannula and the left cannula. Typically, the monkey started drinking within a few minutes following the microinjection and, depending on the dose, would drink continuously for 10-20 min followed by intermittent drinking for another 30-45 min. Text- fig. 1 shows a drinking pattern in response to three bilateral injections of 50 ng of angiotensin II in the ventromedial aspect of the septum (see inset). Eating rarely occurred during the 1 hr period following intracranial microinjections of angiotensin II, especially if the dose was above 100 ng in sensitive tissue sites (see Table 1 ). The drinking response to angiotensin II appeared to be highly motivated since the few attempts either to manually distract or to disturb the monkey by intense visual staring interrupted drinking only momentarily, after which vigorous drinking resumed.
The degree to which angiotensin II was effective as a stimulus to drink depended on the dose, sequence and site of the injection. For example, Table 1 shows that the most effective drinking without eating was evoked by angiotensin II at the higher doses (100-1000 ng) following the first microinjection of a sequence into the septum and anterior hypothalamicpreoptic region (94% of the microinjections).
Text- fig. 2 shows that the anatomical distribution of these active sites (filled circles) extends from A 16-0 to A 18S0, (Russell, 1961) principally in a medial zone of tissue which includes the anterior hypothalamus, the preoptic area, the medial and lateral septum, the nucleus accumbens, the medial aspect of the caudate nucleus and the bed nucleus of the stria 599 L. G. SHARPE AND L. W. SWANSON terminalis (not labelled). There were no discernible differences among these active rostral points in terms of their sensitivity to angiotensin II.
Ranked second to the above was the first microinjection of a sequence of angiotensin II at the higher doses (100-1000 ng) in the mid-brain central grey region (85% of the microinjections, Table 1 ) at A 1.5 (Snider & Lee, 1961) . Points where angiotensin II activated drinking were located next to the aqueduct and the dorsal raphe nucleus (Text- fig. 2 ). Ranked third in sensitivity were injections near the foramen of Monro into the lateral ventricles at A 13-0 and the upper portion of the 3rd ventricle at A 15-0 (Text- fig. 2 ), where angiotensin II evoked drinking without eating 50% to 75% of the time (Table 1) . Representative histology with cannula tracks in active tissue sites is shown in P1. 2.
Relatively inactive points (open circles, Text- fig. 2 ) to angiotensin IIinduced drinking are depicted in the anterior commissure at A 17-0. The small volumes ingested following injections into the anterior commissure loo INTRACRANIAL ANGIOTENSIN AND THIRST occurred after a mean latency 3 times that for points dorsal and ventral to the anterior commissure (see below). It was therefore assumed that the anterior commissure was insensitive and that angiotensin II injected here diffused to adjacent, more active, extra-commissural tissue.
Other relatively inactive sites, where drinking was elicited in less than 50% of the microinjection experiments, were: the mid line thalamus at A 13-0; the medial region of the dorsal and ventral aspect of the mid-brain reticular formation; and parts of the metencephalon at P 3 0 which include the cerebellum, the 4th ventricle and the dorsal aspect of the pons (Table 1 and Text- fig. 1 ). In general, the percentage of eating was higher following injections of angiotensin II in non-sensitive drinking sites. In most instances, several microinjections into the same site over many days did not diminish the effectiveness of angiotensin II in evoking the drinking response. In the septum and anterior hypothalamic-preoptic regions, each active point received an average of twenty-eight microinjections of angiotensin II and other substances with a range of eleven to sixty-one microinjections. Only one animal showed a substantial reduction in water intake over several days after about fifty microinjections into the same site. However, when the inner injection cannula was lowered 1-2 mm INTRACRANIAL ANGIOTENSIN AND THIRST deeper into the brain, microinjections of effective doses of angiotensin II restored the drinking response. All other active points, some with totals of thirty, forty-two, fifty-seven and fifty-eight microinjections, were as sensitive to angiotensin II at the end of the microinjection experiments as at the beginning.
Dose-response relations and bilateral vs. unilateral microinjections of angiotensin II Dose-response curves for bilateral and unilateral microinjections (MI) of angiotensin II into active rostral sites are shown in Text- fig. 3 . A mean of seven microinjection experiments are represented at each dose point with a S.E. of the mean (vertical line). There was a range of from three to fourteen microinjections for each dose. Because 'tachyphylaxis' occurred at the higher doses (100-1000 ng, see below) only the first microinjection in an experimental day was plotted. When administered bilaterally, angiotensin II in doses as low as 0-75-6 ng proved to be an effective dipsogen. Increasing the dose of angiotensin II produced a corresponding average increase in water intake during a 1 hr period, except at the highest doses. The most potent doses ranged from 250 to 1000 ng. The primary difference between bilateral and unilateral microinjections ofangiotensin II is that animals drank less following unilateral microinjections when doses were less than 50 ng. Water intake following angiotensin II was statistically significant from saline control intake at doses 3 ng or above for . Anatomical distribution of sensitive drinking sites (0) and inactive drinking sites ( 0) to 10 #ul. injections of angiotensin II in doses of 100-250 ng. AC = anterior commissure; ANT = anterior hypothalamus; aq = aqueduct; CAU = caudate nucleus; CC = corpus callosum: CCS = commissure of the superior colliculus; DB = diagonal band of Broca; DM = dorsomedial hypothalamic nucleus; DR = dorsal raphe nucleus; F = fornix; FF = fields of Forel; GC = central grey region; GP = globus pallidus; LC = locus coeruleus; LHA = lateral hypothalamic area; LS = lateral septal nucleus; LV = lateral ventricle; MM = medial mammillary nucleus; MS = medial septal nucleus; NAC = nucleus accumbens; NCS = central superior nucleus; NRa = raphe nucleus; NST = nucleus of the spinal tract; Nev7 = facial nerve; N4 = trochlear nucleus; N6 = abducens nucleus; N7 = facial nerve nucleus; OC = optic chiasm; OLM = inferior olivary nucleus, medialis; OLP = inferior olivary nucleus, principalis; OT = optic tract; PbM = medial parabrachial nucleus; PCS = superior cerebellar peduncles; PH = posterior hypothalamus; PO = preoptic area; PP = cerebral peduncle; PV = paraventricular nucleus; Py = pyramidal tract; RF = reticular formation; RN = reticular nucleus of the thalamus; RTP = reticular nucleus of the tegmental pons; VA = ventral anterior nucleus of the thalamus; VM = ventromedial hypothalamic nucleus; V4 = fourth ventricle; ZI = zona incerta; 3V = third ventricle. L. G. SHARPE AND L. W. SWANSON bilateral microinjections and 50 ng or above for unilateral microinjections (P = < 0'01, t test).
Response latencies to angiotensin II The mean drinking latencies following microinjections of angiotensin II into various loci are presented in Text- fig. 4 . There were no differences in drinking latencies among the different doses of angiotensin when micro- Only the first microinjection in a series was plotted. Vertical lines = s.E. of mean; number of injections at each dose ranged from 3 to 14 with a mean of 7.
injected into a particular site. shows no statistical difference among the latencies of the first, second and third microinjections of angiotensin II within an experimental day. The mean drinking latencies ranged from 2'12 to 3*19 min for active points in the septum, anterior hypothalamus, preoptic region and the central grey. The raw latency scores within these active points ranged from 0 0 to 8-0 min. Microinjections of angiotensin II into the anterior commissure produced a mean drinking latency of 7.54 min, about 3 times that of active points surrounding the anterior commissure (P = < 0 01, t test). When compared to active rostral points, the active ventricular sites had significantly longer drinking latencies 604 following microinjections of angiotensin II (P= < 0-01, t test). The longest latencies occurred in the few observations of drinking without eating which followed microinjections of angiotensin II into inactive sites of the mid-brain reticular formation and the metencephalon (P = < 0.01, t test, compared with active rostral points).
Drinking to angiotensin IH analogues and carbachol Table 2 shows that, of all the other substances microinjected into the septum and the anterior hypothalamic-preoptic region, only the decapeptide L. G. SHARPE AND L. W. SWANSON angiotensin I elicited drinking comparable to angiotensin II. When drinking without eating occurred, the mean water intake for the saline control microinjections was 23 ml., as compared to an average 12 ml. intake when including all microinjections (Text- fig. 3 ). Presented collectively, the angiotensin II analogues were relatively ineffective dipsogens (13% of the microinjections), but when drinking occurred these analogues had a short drinking latency, which is similar to angiotensin IL. Among the analogues, Phe4, Tyr8-angiotensin II (P4T8) elicited the most drinking (mean = 74 ml.), but eating occurred in four out of five microinjections. Ile8-angiotensin II, in doses of 500 ng, elicited a mean intake of 19 ml. in a total of seven microinjections. The 1-7 heptapeptide, des-Phe8-angiotensin II (des-Phe8) was the least potent dipsogen (mean = 11 ml.) with eating occurring in nine out of the eleven microinjections. Carbachol in doses ranging from 0-25 to 25 ,g was also ineffective as a stimulus to drinking when microinjected into the rostral tissue sites of the monkey.
Intracranial angiotensin II and 24-hr water intake
To test the effect that intracranial angiotensin may have on daily water intake, the amounts of water consumed in a 24 hr period before, during and after an experimental day were compared. Only the data in which drinking to intracranial angiotensin II exceeded a total of 100 ml. of water during an experimental day were taken. The doses of angiotensin II were 100-250 ng with two to three microinjections in the positive sites of the rostral zone and central grey region of five animals. A total of twenty-eight observations which met the above criteria are presented in Text- fig. 5 . Since daily intakes of water vary considerably between animals, the data are expressed in terms of mean percentage of base line intakes 24 hr before 606 INTRACRANIAL ANGIOTENSIN AND THIRST the experimental day (PRE). shows that the amount of water consumed during the one-hr period following two to three microinjections of angiotensin II (shaded area) is equal to that of normal daily intakes (open bar). The double amount of total water intake during the ex-perimental day (EXP) is statistically significant from base line (PRE, P = < 0.01, t test). The drinking evoked by angiotensin II (shaded area, EXP) represents a mean time of 2*5 hr during the first few hours of the experimental day. There was no compensatory reduction of water intake during either the remaining hours of the experimental day (open bar, EXP) or 24 hr following the experimental day (POST). . Water intake 24 hr before (PRE), during (EXP), and after (POST) an experimental day in which 100-250 ng of angiotensin II was microinjected into the septum, anterior hypothalamus, preoptic region and mesencephalic central grey. A total of twenty-eight observations are represented. Shaded area represents post-injection water intake, following two to three microinjections of angiotensin II (AII). Vertical lines = s.E:.
Of mean.
Intake reduction to repeated injec~tions of angiotensin II In the higher dose range of angiotensin II (100-250 ng), water intake was much larger during the howlr following the first microinjection than that of the second or third (Texrt-fig. 6 ). The mean time interval was 1-8 hr between the first and second microinjection and 14 hr between the second and third. There was a 55% and 74% drop in water intake on the second and third microinjections, respectively (P = < 0 01, t test, compared to the first microinjection).
This reduction in response magnitude to sequential injections of angiotensin II appeared to be related more to the amount of water drunk after the first microinjection than to dose per se. For example, in nine observations where the mean intake was 230 ml. following the first microinjection of 100-250 ng angiotensin II, the second and third microinjections had means of 18 and 20 ml. of water intake, respectively, values much lower than intakes shown in Text- fig. 6 for the second and third microinjection. In three cases where drinking was prevented following the first microinjection of 100 ng angiotensin II, the second microinjection resulted in a mean intake of 118 ml., which is normal for this dose when given as the first microinjection. Only 70 ml. water was drunk after the third microinjection. In general, little or no reduction was observed if 50 ml. or less of water was drunk following microinjections of angiotensin II, regardless of dose. Thus, the reduction in the magnitude of the drinking response to sequential injections of angiotensin II appears to be due not to tachyphylaxis in the pharmacological sense, but to dilutional inhibition of subsequent water intake due to the water already drunk.
Effects of drug pre-treatment on angiotensin I and angiotensin II
Attempts to alter the amount of water intake of angiotensin I and II by pre-treatment with various drugs are presented in Text- fig. 7 . All microinjections were made in the septum, anterior hypothalamus and preoptic region. The pre-treatment drugs were microinjected 10 mm before the dipsogens in the same brain site. (lle8-A II), 250 ng angiotensin II alone (A II) and 500 ng Ile8-angiotensin II followed by 250 ng angiotensin II (I1e8-AII +All). D, microinjection of 500 ng carbachol alone (Car), 100 ng angiotensin IT alone (All) and 500 ng carbachol followed by 100 ng angiotensin II (Car + A II). All pretreatment drugs were microinjected into active rostral sites (septum, anterior hypo. thalamus and preoptic area) 10 min before microinjections of angiotensin I or II. All microinjection experiments (numbers above bars) were separated by 48 hr. Vertical lines _ s.F. of mean.
L. C. SHARPE AND L. W. SWANSON SQ 20,881, an inhibitor of the enzyme which converts angiotensin I to angiotensin II (converting enzyme), has been reported to prevent the cardiovascular (Engel, Schaeffer, Gold & Rubin, 1972; Bianchi, Evans, Cobb, Peschka, Schaeffer & Laffan, 1973) and drinking (Severs, Summy-Long & Daniels-Severs, 1973) responses to angiotensin I but not angiotensin II. Text- fig. 7A shows that pre-treatment with microinjections of 1*0-25 ,tg of SQ 20,881 had no significant influence on the dipsogenic action of 100 ng angiotensin I. Fitzsimons & Setler (1971) reported that interfering with catecholamine systems in the diencephalon disrupted drinking elicited by angiotensin II. By destroying catecholamine receptors with microinjections of 6-hydroxydopamine or by blocking catecholamine receptors with pre-treatments of haloperidol, the drinking response to angiotensin II was markedly reduced. However, in this study, pre-treatment with 5 and 10 ,g of haloperidol failed to produce a reduction in the dipsogenic effect of 100 ng of angiotensin II (Text- fig. 7B ).
An analogue of angiotensin II, Ile8-angiotensin II, has been shown to block the pressor action of angiotensin II in vivo and its myotropic action in vitro (Needleman, Johnson, Vine, Flanegan & Marshall, 1972) . Text- fig. 7C shows that pre-treatment with a 500 ng microinjection of Ile8angiotensin (Ile8-AII) had no blocking action on the drinking response to 250 ng angiotensin II.
Carbachol, a potent dipsogen when given intracranially to rats (Grossman, 1960) but not to monkeys (Myers, 1969) , had no potentiating or blocking effects on angiotensin II-induced drinking when microinjected in doses of 500 ng 10 min before 100 ng angiotensin II (Text- fig. 7D ).
Angiotensin II and the sodium hypothesis
Previous reports that a synergistic action exists between angiotensin and hypertonic NaCl in the drinking response of the goat suggest that Na+ ions mediate the effect of angiotensin on central thirst mechanisms (Andersson, Eriksson & Oltner, 1970; Andersson & Eriksson, 1971 ). To test -the possible interaction between angiotensin II and NaCl, 100 ng angiotensin II was either dissolved in sterile distilled water or' in various concentrations of sterile NaCl solutions. Injections of 10 dUl. were made into the septum, the preoptic region, the ventricles and the mid-brain central grey in the water-replete monkey. Since no difference was found among the different sites with respect to amount of water consumed, the data were combined. Text- fig. 8 shows that control injections of NaCl in concentrations of 154 and 330 mm (n = 18) were followed by a mean intake of 17 ml.
Angiotensin II produced a significant increase in water intake, but the 610 611 amount drunk was not significantly altered by various types of vehicles consisting of distilled water and three different concentrations of NaCl (154, 330 and 850 mM . Mean water intake in response to microinjections of 100 ng angiotensin II (A II) dissolved in either distilled water (dist. H20), isotonic saline (154 mM-NaCl) or hypertonic saline (330-850 mM NaCI). Since water intake did not differ between 154 and 330 mM-NaCl microinjected alone or between 330 and 850 mm microinjected as vehicles to angiotensin II, these data were combined. All positive drinking sites were involved. Vertical lines = s.E. of mean. Numbers above bars = number of microinjection experiments.
Other responses to intracranial angiotensin II
As can be seen in Table 3 , the second most noticeable response to microinjections of angiotensin II into active rostral sites (septum, anterior hypothalamus and preoptic area), was yawning. Yawning behaviour typically began soon after the monkey stopped drinking or between drinking bouts, with latencies ranging from 5 to 45 min following a microinjection of angiotensin II. The number of yawns varied from a few to as high as 45, depending on substance, dose and site of injection. The highest mean number of yawns was elicited by microinjections of high doses of angiotensin II into the most rostral (Sep, Ant & PO) and the most caudal (cerebellum, 4V and Pons) points tried, and were significantly different from saline controls. When injections were made into active rostral sites a doseresponse relation was indicated between angiotensin II and yawning since L. G. SHARPE AND L. W. SWANSON 
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INTRACRANIAL ANGIOTENSIN AND THIRST the lower doses (0.5-50 ng) produced significantly less yawning than the higher doses (100-1000 ng). The percentage of microinjections in which yawning occurred did not correlate with the mean number of yawns.
Yawning frequency was not related to active angiotensin drinking sites nor did it appear to be related to the occurrence of sleep or drowsiness.
Since behavioural drowsiness (eyes closed and relaxation) was frequently seen, a total of forty e.e.g. samples were taken for 1-2 hr following a microinjection. Sleep was defined as a change from the awake state of low voltage/high frequency e.e.g. patterns to relatively high voltage and lower frequency e.e.g. patterns combined with behavioural drowsiness. In Table 3 , percentage data for sleep and drowsiness were combined and are assumed to be one and the same. The type of sleep, regardless of site injected, was largely light sleep, defined as stages 1 and 2. The animals were easily aroused from sleep at all times. Very little deep slow-wave sleep or paradoxical sleep patterns were ever observed.
Temperature responses, recorded from a brain thermistor, are presented in Table 3 as the percentage of microinjections in which temperature changed at least 0. 10 within 15 min following a microinjection. For almost every site, mioroinjections of angiotensin II were followed by more temperature decreases than increases. Injections of carbachol into rostral sites were the only exception. The predominant number of temperature decreases appeared to be related more to sleep than to a direct effect of angiotensin II. The amount of water drunk to microinjections of angiotensin II was unrelated to decreases in temperature. Vocalization and hyperactivity were seldom observed. The most noticeable instances were from two monkeys that were injected with the higher doses (100-1000 ng) of angiotensin II into the lateral and third ventricles. The hyperactivity of one animal (male) was characterized by struggling against restraint and displaying frustrated attempts to grab the tubing and e.e.g. leads connected to the head region. The other monkey (female) displayed vocalization and hyperactivity characterized by episodes of vigorous struggling lasting 30-40 sec followed by short periods of complete motionlessness and fixed staring into space. During the hyperactive phase, which seldom lasted more than 30 min, there were stereotyped movements of the head and arms. The type of vocal noise consisted almost completely of the short bark normally associated with agonistic behaviour (Rowell & Hinde, 1961) , and occurred more frequently in conjunction with hyperactivity. Little or no drinking was observed during the hyperactive stage. 613 L. G. SHARPE AND L. W. SWANSON DISCUSSION We have shown that angiotensin II is a very potent dipsogen when administered intracranially at specific sites in the water-replete monkey. The fact that the septum, anterior hypothalamus and preoptic region were very sensitive dose-responsive drinking points to angiotensin II supports previous studies of angiotensin II-induced drinking in the rat (Epstein et al. 1970; Swanson, Sharpe & Griffin, 1973) . These medially located forebrain points have also been demonstrated to be sensitive dipsogenic loci to intracranial carbachol in the rat (Fisher & Coury, 1962; Antunes-Rodrigues & Covian, 1971) , but not in the monkey (Sharpe & Myers, 1969) or in other species (Myers & Sharpe, 1968) . In contrast to carbachol and other cholinomimetics, angiotensin II injected intracranially elicits a highly specific drinking response in all species tried to date (Setler, 1971; Fitzsimons, 1972; Myers et al. 1973; Sturgeon et at. 1973) .
Another almost equally sensitive region to angiotensin II-induced drinking was found in the mesencephalic central grey located about 14-5 mm posterior to the active drinking sites of the anterior hypothalamus. The central grey region in the rat was also recently shown to be an active drinking site to angiotensin II but not to carbachol . It is interesting to note that lesions of the mesencephalic central grey, which includes the serotonin containing cell bodies of the dorsal raphe, produced a transient increase in water intake in rats (Lorens, Sorensen & Yunger, 1971; Coscina, Grant, Balagura & Grossman, 1972) , while in an earlier study serotonin was the only biogenic amine that occasionally produced drinking without eating when microinjected into diencephalic-mesencephalic border regions in the monkey (Sharpe & Myers, 1969) . Even though injections were not made into the mammillary complex during this study, Myers et al. (1973) have recently reported that intracranial injections of angiotensin, as well as nicotine, into this area produced drinking in the monkey.
Of the areas tested, the cerebral ventricles (near the foramen of Monro) ranked third in sensitivity to angiotensin II-induced drinking ( Table 1) . The latency to drink was significantly longer when compared to active rostral as well as to active mesencephalic sites. In comparison, no drinking occurred when angiotensin II was injected into the 4th ventricle. Others have also found that angiotensin II injected intraventricularly near the 3rd ventricle results in drinking (Myers et al. 1973; . It is possible that these results are due to involvement of periventricular sites, such as the subfornical organ (Simpson & Routtenberg, 1973) .
It is unlikely that the dipsogenic effects of angiotensin II, when injected INTRACRANIAL ANGIOTENSIN AND THIRST into tissue sites, were due to diffusion of the polypeptide from the injection site, either up the cannula track or via the ventricles or vasculature to other sites (Routtenberg, Sladek & Bondareff, 1968; Routtenberg, 1972) . For example: (1) intraventricular injections of angiotensin II had longer drinking latencies and produced more side effects than angiotensin II applied to sensitive tissue sites; (2) the positive drinking sites of the mesencephalic central grey region had comparable short drinking latencies and are far posterior to the subfornical organ and other rostral drinking points;
(3) the mid line thalamus was an inactive drinking site even though the cannula penetrated the ventricular lumen at a point near the subfornical organ; (4) in the rat , very small volumes (0.1 /A4. solution) of angiotensin II very often produced drinking when applied at points more ventral and lateral to the ventricles than inactive sites. However, until it is demonstrated that locally applied substances, such as radioactive labelled angiotensin II, are transported in sufficient time and quantity to another sensitive site, such as the subfornical organ, this question of ventricular and vasculature involvement remains controversial Myers, Tytell, Kawa & Rudy, 1971) .
Tachyphylaxis to angiotensin is a well-demonstrated phenomenon in many peripheral biological systems. Successive doses of angiotensin have been shown to result in a diminution of the pressor response (Cline, 1971; Gross, Bock & Turrian, 1961) and a reduction in the contraction of isolated organs (Gross, 1971; Khairallah, Page, Bumpus & Tiirker, 1966; Palaic & Lemorvan, 1971) . With regard to the monkey's drinking response, tachyphylaxis to angiotensin II was demonstrated as a reduction in water intake of more than one half on the second and third microinjections which were separated by temporal intervals of from I 0 to 2 5 hr. It is not likely that this tachyphylaxis was due to a loss of strength or stability of angiotensin II over time because (1) when the first microinjection of angiotensin was made from 4 to 5 hr after the preparation of the solution a maximal drinking response for that dose was still evoked and (2) in the few occasions where fresh solutions of angiotensin II were prepared for the second microinjection, marked reductions in fluid intake as compared to the first microinjection were still demonstrated. The most likely explanation for this tachyphylaxis appears to be related more to the amount of water drunk on the first microinjection than to the dose per se. Therefore, it appears that monkeys drink less water following successive injections of angiotensin II because of negative feed-back or satiation signals from previously ingested water (dilutional inhibition). This is supported by time-response experiments on rats, showing that cessation of drinking after 10-15 min following intracranial angiotensin II is due to satiating factors of water intake rather than the dissipation of the drug effect . Similar 615 L. G. SHARPE AND L. W. SWANSON results were found with carbachol-induced drinking in the rat, including the fact that stomach loading with water also inhibited water intake to intracranial carbachol (Quartermain & Miller, 1966) . However, until more systematic studies are done on this problem, the more traditionally accepted mechanisms of tachyphylaxis, such as the interaction of angiotensin II with specific receptors, with chemical mediators, with enzyme systems, or with storage mechanisms, cannot be discarded.
Microinjections of 100 ng of angiotensin II dissolved in 1 0'l. hypertonic saline (330 mm and 850 mM) had no influence on water intake when compared with the same dose of angiotensin II dissolved in vehicles of distilled water or isotonic saline (154 mm; Text-fig. 8 ). The injection sites were widespread, including the preoptic region, the septum, the third ventricle and the mesencephalic central grey. In a recent report from this laboratory (Swanson, Sharpe & Griffin, 1973) , the only occasion in which hypertonic NaCl solutions (800 mm) increased water intake was when used as a vehicle for threshold doses of angiotensin II microinjected into the septum and medial preoptic area of the rat. The above studies on rats and monkeys show that the presence of NaCl in different concentrations in the injection solution does not influence the drinking response to doses of angiotensin II above the threshold range. This is not to imply that angiotensin has no interaction with endogenous Na+, as it is possible that one of its mechanisms of action is a nonspecific influence on the transport of Na+ in many brain regions. Angiotensin II has been shown to enhance the transport of sodium across many types of peripheral membranes (Koch-Weser, 1965; Blair-West & McKenzie, 1966; Villamil, Nachev & Kleeman, 1970) . However, the extent to which angiotensin produces its dipsogenic activity by acting on specific osmoreceptors (Blass & Epstein, 1971; Peck & Novin, 1971) or ventricular Na+ receptors (Andersson, 1971) , requires further study.
The decapeptide precursor, angiotensin I, was as effective as angiotensin II in causing monkeys in normal water balance to drink at the dose tested. Among the analogues of angiotensin II that were tested, Phe4, Tyr8angiotensin II was the most potent dipsogen, followed by Ile8-angiotensin II, with des-Phe8-angiotensin II having little or no dipsogenic effect (Table   2 ). These results are in general agreement with recent rat studies in our laboratory (Swanson, Marshall, Needleman & Sharpe, 1973) and with those of Fitzsimons (1971) who found that precursor peptides were highly effective dipsogens, whereas the removal of phenylalanine in position 8 (a 1-7 heptapeptide, des-Phe8-angiotensin II) produced an inactive compound. As in previous studies (Myers, 1969; Sharpe & Myers, 1969) , carbachol had no dipsogenic activity in the monkey.
The C-terminal substituted analogues, Jle8-angiotensin II and Phe4_ INTRACRANIAL ANGIOTENSIN AND THIRST Tyr8-angiotensin II, have been demonstrated to be potent antagonists of angiotensin II in vitro (rat uterine strips) and in vi? 'o (pressor response; Needleman et al. 1972 ). However, no antagonism of the drinking response was found with a microinjection pre-treatment of Ile8-angiotensin II in the monkey or the rat (Swanson, Marshall, Needleman & Sharpe, 1973 ), suggesting that the type of receptor-drug interaction to angiotensin II and its analogues is different for peripheral and central nervous tissue.
Reports that the brain contains renin, angiotensin I and the angiotensinconverting enzyme (Fischer-Ferraro, Nahmod, Goldstein & Fenkielman, 1971; Ganten, Marquez-Julio, Granger, Hayduk, Karsunky, Boucher & Genest, 1971; Ganten, Minnich, Granger, Hayduk, Brecht, Barbeau, Boucher & Genest, 1971; Yang & Neff, 1972) promotes the view that the dipsogenic action of angiotensin I results from its conversion to angiotensin II. However, pre-treatment with the potent inhibitor of angiotensinconverting enzyme, SQ 20,881, had no inhibitory action on the dipsogenic effects of angiotensin I in the monkey, even though the ratios of SQ 20,881 to angiotensin I were as high as 250:1. The failure of SQ 20,881 to inhibit angiotensin I-induced drinking is in agreement with the results of rat studies by Swanson, Marshall, Needleman & Sharpe (1973) and by Bryant & Falk (1973) , but is in disagreement with the results of Severs et al. (1973) , who found that pre-treatment with intraventricular injections of SQ 20,881 inhibited the polydipsic action of angiotensin I, but not angiotensin II. This discrepancy is discussed in detail by Bryant & Falk (1973) . One likely explanation, related to the results of this study, is that the experimental design of the Severs et al. (1973) study allowed for dilutional inhibition to develop since the time interval was only 45 min between the control injection of angiotensin I and the injection of SQ 20,881 (followed by angiotensin I 15 minutes later). It is also possible that higher ratios in the order of 1000:1 are needed between SQ 20,881 and angiotensin I for this converting enzyme inhibitor to block the drinking response to intracranial angiotensin I and other peptide precursors (Epstein, Hsiao & Johnson, 1973) . Pre-treatment with microinjections of haloperidol, presumably a catecholamine-blocking agent, failed to inhibit drinking evoked by angiotensin II in the monkey. Other similar negative results were found in the rat with pre-treatments of haloperidol as well as other adrenergic blockers (Covian, Gentil & Antunes-Rodrigues, 1972; Swanson, Marshall, Needleman & Sharpe, 1973) . The above evidence does not support the hypothesis that central catecholaminergic neural systems are involved in the mediation of the angiotensin drinking response (Fitzsimons & Setler, 1971; Severs et al. 1971) . Thus far, only the pretreatment with intracranial microinjections of angiotensin II antiserum (Epstein, Fitzsimons & Johnson, L. G. SHARPE AND L. W. SWANSON 1972) has been found to be a consistent and effective blocking agent of angiotensin-induced drinking.
Yawning was the only response besides drinking that appeared to be directly related to intracranial injections of angiotensin II in the monkey. The response appeared to be spontaneous, reflexive and dose-related, but did not seem to be related to the occurrence of sleep or to the stimulation of active drinking sites. The onset of yawning was within 5 min of the microinjection if no drinking occurred, or if non-drinking sites were stimulated with angiotensin II. Inasmuch as other injected substances have not elicited yawning, the significance of the angiotensin-yawning relation is unclear.
Microinjections of angiotensin II into brain tissue were almost always followed by a calm relaxing state of the animal, characterized principally by periods of quietude and light sleep with moderate falls in body temperature. Even at the highest doses tested (10-1 5#,g) there were no behavioural signs of drug toxicity, even though water intake was less than maximal. This is also the case for angiotensin-induced drinking in the rat, whereas carbachol in the higher doses produced less than the maximal drinking response because of toxic effects, such as hyperactivity and convulsions (Miller, Gottesman & Emery, 1964; Swanson, Sharpe & Griffin, 1973) . In the monkey, behavioural excitation to angiotensin II was observed more often following intraventricular injections, which may have been due to the transport of angiotensin through the cerebrospinal fluid to act on sensitive sites that border the ependymal wall and play a role in the mediation of blood pressure or sympathetic activation (Deuben & Buckley, 1970; Andersson, Eriksson & Fernandez, 1971; Severs et at. 1971) .
Most of the available evidence suggests that the main role of the renin-angiotensin system in the central control of body water maintenance is its action on neural components of hypovolemic or extracellular thirst as opposed to cellular thirst (Epstein, 1973; Fitzsimons, 1972) . However, it is still far from clear how angiotensin acts on central nervous tissue to activate drinking behaviour or what types of neurochemical systems are involved in the mediation of angiotensin-induced thirst.
